Table 1.

Patient and treatment characteristics of all patients

	IDAC (n = 178)	HiDAC (n = 642)	p value	p value (after PS weighting)
Age at initial diagnosis (years, median (IQR))	58.5 years (IQR, 49–62)	50.0 years (IQR, 41–56)	< 0.001	0.246
Female sex, no./no. Available (%)	88/178 (49.4%)	314/642 (48.9%)	0.968	0.867
AML type, no./no. available (%)
de novo AML	147/178 (82.6%)	594/640 (92.8%)	< 0.001	0.852
sAML	9/178 (5.1)	20/640 (3.1)
tAML	22/178 (12.4)	26/640 (4.1)
ELN-Risk 2017 group, no./no. available (%)
Favorable	67/165 (40.6)	336/600 (56)	< 0.001	0.915
Intermediate	74/165 (44.8)	225/600 (37.5)
Adverse	24/165 (14.5)	39/600 (6.5)
Core binding factor AML	20/168 (11.9)	116/604 (19.2)	0.037	0.585
Complex karyotype, no./no. available (%)	15/168 (8.9)	29/609 (4.8)	0.060	0.182
FLT3-ITD	38/161 (23.6)	123/595 (20.7)	0.486	0.927
NPM1 mut	68/168 (40.5)	280/612 (45.8)	0.258	0.663
HCT-CI
0–1	100/178 (56.2)	498/641 (77.7)	< 0.001	0.595
2–4	78/178 (43.8)	143/641 (22.3)
Induction therapy
1 Cycle 7 + 3	67/178 (37.6)	151/642 (23.5)	< 0.001	< 0.001
2 Cycles 7 + 3	75/178 (42.1)	428/642 (66.7)
7 + 3/HAM	8/178 (4.5)	33/642 (5.1)
Others	28/178 (15.7)	30/642 (4.7)
Number of consolidation cycles (median (IQR))	2 (IQR,1–3)	3 (IQR,2–3)	< 0.001	< 0.001
Cytarabine dose per chemo-consolidation cycle (median (IQR))	5891.85 mg/m2 per cycle	17,580.38 mg/m2 per cycle	< 0.001	< 0.001
Additional substances	5/178 (2.8)	10/642 (1.6)	0.432	0.107
Allogeneic HCT in CR1	67/178 (37.6)	127/642 (19.8)	< 0.001	< 0.001
Allogeneic HCT salvage	36/178 (20.2)	198/642 (30.8)	0.007	0.017

HiDAC/IDAC high-dose/intermediate-dose cytarabine; IQR interquartile range; sAML secondary AML; tAML treatment-related AML; HCT-CI hematopoietic cell transplantation-comorbidity index; 7 + 3 induction treatment with standard-dose cytarabine for 7 d and daunorubicin for 3 d; HAM high-dose cytarabine plus mitoxantrone; HCT hematopoietic cell transplantation; CR1 first complete remission; PS propensity score